Gencurix Inc
229000
Company Profile
Business description
Gencurix Inc develops diagnosis treatment kits. The company focuses on developing molecular diagnostic tests based on core technologies of liquid biopsy and biomarker discovery. It offers products including GenesWell BCT, a breast cancer test, GenesWell ddEGFR Mutation Test, Droplex, eDX, Geno CTC, and others.
Contact
243 Digital-ro
15th floor, Jiha City
Guro-gu
Seoul
KORT: +82 7074329481
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
69
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Microsoft’s earnings report is expected to touch on AI adoption and monetization.
stocks
World’s largest miner overvalued after solid quarter
The ongoing war is likely to keep commodity prices even more volatile than usual until it is resolved.
stocks
Hidden value in an expensive ASX
How investors can uncover value beyond the index heavyweights.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,999.20 | 52.20 | -0.58% |
| CAC 40 | 8,156.43 | 79.28 | -0.96% |
| DAX 40 | 24,194.90 | 75.97 | -0.31% |
| Dow JONES (US) | 49,490.03 | 340.65 | 0.69% |
| FTSE 100 | 10,476.46 | 21.63 | -0.21% |
| HKSE | 25,870.37 | 292.87 | -1.12% |
| NASDAQ | 24,657.57 | 397.60 | 1.64% |
| Nikkei 225 | 59,009.00 | 576.86 | -0.97% |
| NZX 50 Index | 12,872.34 | 73.26 | -0.57% |
| S&P 500 | 7,137.90 | 73.89 | 1.05% |
| S&P/ASX 200 | 8,768.10 | 51.40 | -0.58% |
| SSE Composite Index | 4,073.71 | 32.54 | -0.79% |